Use App
AI Agent
Trending
News
Earnings
All
DIA
1.87%
SPY
3.64%
QQQ
5.67%
Trending
CASHCAT
10.27%
REPL
0.83%
ABVX
9.24%
MRK
0.69%
NEAR
4.48%
AZN
0.60%
BONK
0.72%
ZM
3.05%
HALO
1.82%
UEC
7.99%
Feed
News
Sentiment
Fundamentals
Info
Home
Symbol
OZEM
News
Exchange:
NASDAQ
·
Updated 07:30 PM EST
OZEM News
News
all
press releases
Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.
Stocktwits
Full Article
Share to Feed
Eli Lilly’s Orforglipron Wins Big In China – Gains Edge Over Novo In Race For Potential $4.5B Market
Orforglipron, which is marketed as Foundayo, became the first weight-loss pill to receive approval in China, according to a Reuters report.
Stocktwits
Full Article
Share to Feed
More News
Hims & Hers Faces A ‘Transition Year’ Amid Increasing AI Investments, Says KeyBanc – Expects Lower Pricing To Weigh On FY2027-2028 Earnings Outlook
Analyst Justin Patterson said Hims & Hers’ focus on lower treatment prices could eventually attract more subscribers and increase the number of treatments per customer.
Stocktwits
Full Article
HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows
Jefferies said a ‘dynamic GLP-1 environment’ would continue to cause volatility in Hims & Hers’ subscriptions
Stocktwits
Full Article
Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears, Says ‘Our World’ Won’t Change Dramatically – NVO Stock Gains Pre-Market
CEO Mike Doustdar told CNBC that while the company has experienced weak growth in the past due to pricing, volumes have grown ‘phenomenally.’
Stocktwits
Full Article
LLY, ABBV Stocks Hit All-Time High – Here’s What’s Driving Investor Enthusiasm Today
LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.
Stocktwits
Full Article
Eli Lilly CEO Cites Growth Beyond Weight Loss In Oncology, Immunology As Key To FY 2026 Outlook Raise – LLY Stock Surges To Record High In Pre-Market
Lilly raised its full-year revenue forecast to $91-92 billion, compared with its previous outlook of $85-87 billion.
Stocktwits
Full Article
LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight Loss
Retatrutide helped patients with type 2 diabetes lose an average of 44 to 47 pounds over 80 weeks, compared with about 21 pounds for Ozempic.
Stocktwits
Full Article
Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months
European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.
Stocktwits
Full Article
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
Stocktwits
Full Article
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks
1
2
Advertisement
|
Remove ads.
Home
Watchlist
Trending
News
Explore
Profile